Thursday, May 11, 2017 3:34:17 PM
"Cleveland BioLabs is very close to commercializing its new drug Entolimod and has other drugs in Phase 2"
"In addition to this, the balance sheet looks very clean right now. The company showed in the last 10-k that it had about $15 million in total assets and only $3 million in total liabilities".
"has no long term debt, and 99% of its assets are short-term investments or cash on hand".
beside Russian Federation Ministry of Industry funding "has also received funding from the US Government".
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM